ReviewOxidative medicine and cellular longevity2018
Metallic Nanoantioxidants as Potential Therapeutics for Type 2 Diabetes: A Hypothetical Background and Translational Perspectives.
Review in Oxidative medicine and cellular longevity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 61 citations in OpenAlex.
- Nanotechnology-Based Plant Antioxidants: A Current Literature Review on Bioavailability and Oxidative Stress.Current nutrition reports · 2025Review
- Metformin-loaded nanoparticles reduce hyperglycemia-associated oxidative stress and induce eNOS phosphorylation in vascular endothelial cells.Scientific reports · 2024Article
- Accelerated Longitudinal Glycemic Changes in Relation to Urinary Toxic/Essential Metals and Metal Mixtures Among Mexican Americans Living in Starr County, Texas.Diabetes care · 2024Article
- Gut microbiome as therapeutic target for diabesity management: opportunity for nanonutraceuticals and associated challenges.Drug delivery and translational research · 2024Review
- Rising Influence of Nanotechnology in Addressing Oxidative Stress-Related Liver Disorders.Antioxidants (Basel, Switzerland) · 2023Review
- Hypoglycaemic activity of biosynthesized copper oxide nanoparticles in alloxan-induced diabetic Wister rats.Endocrinology, diabetes & metabolism · 2023Article
- The interplay between androgens and the immune response in polycystic ovary syndrome.Journal of translational medicine · 2023Review
- An Overview of Nanomaterial Applications in Pharmacology.BioMed research international · 2023Review
- Mistletoe infestedFood chemistry. Molecular sciences · 2022Article
- Low-Molecular-Weight Synthetic Antioxidants: Classification, Pharmacological Profile, Effectiveness and Trends.Antioxidants (Basel, Switzerland) · 2022Review
- Nanoformulation of Plant-Based Natural Products for Type 2 Diabetes Mellitus: From Formulation Design to Therapeutic Applications.Current therapeutic research, clinical and experimental · 2022Review
- Nanoantioxidants: Pioneer Types, Advantages, Limitations, and Future Insights.Molecules (Basel, Switzerland) · 2021Review
- Review
- Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds.International journal of nanomedicine · 2020Review
- Article
- Nanodelivery of Natural Antioxidants: An Anti-aging Perspective.Frontiers in bioengineering and biotechnology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperglycemia-induced overproduction of reactive oxygen species (ROS) is an important contributor to type 2 diabetes (T2D) pathogenesis. The conventional antioxidant therapy, however, proved to be ineffective for its treatment. This may likely be due to limited absorption profiles and low bioavailability of orally administered antioxidants. Therefore, novel antioxidant agents that may be delivered to specific target organs are actively developed now. Metallic nanoparticles (NPs), nanosized materials with a dimension of 1-100 nm, appear very promising for the treatment of T2D due to their tuned physicochemical properties and ability to modulate the level of oxidative stress. An excessive generation of ROS is considered to be the most common negative outcome related to the application of NPs. Several nanomaterials, however, were shown to exhibit enzyme-like antioxidant properties in animal models. Such NPs are commonly referred to as "nanoantioxidants." Since NPs can provide specifically targeted or localized therapy, their use is a promising therapeutic option in addition to conventional therapy for T2D. NP-based therapies should certainly be used with caution given their potential toxicity and risk of adverse health outcomes. However, despite these challenges, NP-based therapeutic approaches have a great clinical potential and further translational studies are needed to confirm their safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.